Envista Holdings Corporation Common stock, $0.01 par value per share
NVSTNYSECIK 1757073Healthcare / Medical Devicesfiscal year ends December36 quarters since 2017
Latest quarter Q3 FY2026, filed November 4, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.
Share price
Daily candlesticks from November 18, 2024 to November 13, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.
The last 16 quarters
Q4 FY2022 to Q3 FY2026, through the filing of November 4, 2026.
Net income losses drawn in red.
Operating cash flow less capital expenditures; negative quarters in red.
Positions at each quarter end, as filed; short-term investments are not included.
Income statement
Last eight quarters, newest first, through Q3 FY2026 filed November 4, 2026.
| Millions of dollars | Q3 FY2026ended Oct 2, 2026filed Nov 4, 2026 | Q2 FY2026ended Jul 3, 2026filed Aug 5, 2026 | Q1 FY2026ended Apr 3, 2026filed May 6, 2026 | Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026 | Q3 FY2025ended Sep 26, 2025filed Oct 30, 2025 | Q2 FY2025ended Jun 27, 2025filed Jul 31, 2025 | Q1 FY2025ended Mar 28, 2025filed May 1, 2025 | Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025 | YoYQ3 FY2026vs Q3 FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 692 | 731 | 706 | 751 | 670 | 682 | 617 | 653 | +3.2% |
| Cost of revenue | 291 | 324 | 315 | 340 | 300 | 312 | 281 | 280 | −2.9% |
| Gross profit | 401 | 407 | 390 | 411 | 370 | 370 | 336 | 373 | +8.2% |
| Research and development | 29 | 30 | 30 | 32 | 28 | 28 | 25 | 27 | +3.5% |
| Selling, general and administrative | 284 | 296 | 298 | 305 | 284 | 295 | 272 | 300 | −0.1% |
| Operating income | 515 | 80 | 63 | 73 | 58 | 46 | 39 | 46 | +796.0% |
| Other income (expense) | (7) | 3 | (3) | (5) | 1 | 2 | (1) | 0 | −614.3% |
| Pretax income | 500 | 74 | 52 | 58 | 50 | 41 | 29 | 37 | +902.4% |
| Income tax | (8) | 21 | 14 | 25 | 80 | 14 | 11 | 35 | −110.1% |
| Net income | 508 | 54 | 39 | 33 | (30) | 26 | 18 | 1 | +1777.6% |
| Diluted EPS ($) | 3.11 | 0.33 | 0.23 | — | (0.18) | 0.16 | 0.10 | — | +1827.8% |
| Diluted shares (millions) | 163 | 164 | 166 | — | 166 | 170 | 174 | — | — |
Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.
Balance sheet
Last eight quarters, newest first, through Q3 FY2026 filed November 4, 2026.
| Millions of dollars | Q3 FY2026ended Oct 2, 2026filed Nov 4, 2026 | Q2 FY2026ended Jul 3, 2026filed Aug 5, 2026 | Q1 FY2026ended Apr 3, 2026filed May 6, 2026 | Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026 | Q3 FY2025ended Sep 26, 2025filed Oct 30, 2025 | Q2 FY2025ended Jun 27, 2025filed Jul 31, 2025 | Q1 FY2025ended Mar 28, 2025filed May 1, 2025 | Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025 | YoYQ3 FY2026vs Q3 FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1,159 | 1,126 | 1,083 | 1,212 | 1,134 | 1,111 | 1,077 | 1,069 | +2.2% |
| Short-term investments | — | — | — | — | — | — | — | — | — |
| Total current assets | 2,002 | 1,958 | 1,919 | 2,027 | 1,948 | 1,935 | 1,850 | 1,788 | +2.7% |
| Total assets | 5,611 | 5,597 | 5,578 | 5,679 | 5,643 | 5,664 | 5,466 | 5,351 | −0.6% |
| Total current liabilities | 816 | 807 | 787 | 853 | 822 | 794 | 873 | 879 | −0.7% |
| Long-term debt | 1,429 | 1,436 | 1,439 | 1,448 | 1,445 | 1,445 | 1,296 | 1,278 | −1.1% |
| Total debt | 1,429 | 1,436 | 1,439 | 1,448 | 1,445 | 1,445 | 1,528 | 1,510 | −1.1% |
| Total liabilities | — | — | — | — | — | — | — | — | — |
| Stockholders’ equity | 3,089 | 3,076 | 3,080 | 3,106 | 3,088 | 3,139 | 3,036 | 2,935 | +0.0% |
| Shares outstanding (millions) | 160 | 161 | 163 | 164 | 164 | 166 | 169 | 172 | — |
Positions at each period end. Long-term debt is the line the filer tags, with or without its current portion. Total debt is one definition across filers, built from filed lines: long-term debt with its current portion plus short-term borrowings, finance leases where the filer folds them into its debt line, operating leases never; it is blank where the tags do not add up to it. Italic figures are derived.
Cash flow statement
Last eight quarters, newest first, through Q3 FY2026 filed November 4, 2026.
| Millions of dollars | Q3 FY2026ended Oct 2, 2026filed Nov 4, 2026 | Q2 FY2026ended Jul 3, 2026filed Aug 5, 2026 | Q1 FY2026ended Apr 3, 2026filed May 6, 2026 | Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026 | Q3 FY2025ended Sep 26, 2025filed Oct 30, 2025 | Q2 FY2025ended Jun 27, 2025filed Jul 31, 2025 | Q1 FY2025ended Mar 28, 2025filed May 1, 2025 | Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025 | YoYQ3 FY2026vs Q3 FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 78 | 119 | (3) | 108 | 79 | 89 | 0 | 132 | −1.0% |
| Capital expenditures | 16 | 15 | 13 | 16 | 11 | 12 | 6 | 9 | +49.1% |
| Free cash flow (CFO − capex) | 62 | 104 | (16) | 92 | 68 | 76 | (6) | 124 | −9.0% |
| Depreciation and amortization | 25 | 28 | 29 | 29 | 29 | 30 | 28 | 28 | −13.0% |
| Share repurchases | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — |
10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.
Annual statements
Every fiscal year filed, newest first, through FY2025 filed February 12, 2026.
Income statement
| Millions of dollars | FY2025ended Dec 31, 2025filed Feb 12, 2026 | FY2024ended Dec 31, 2024filed Feb 13, 2025 | FY2023ended Dec 31, 2023filed Feb 15, 2024 | FY2022ended Dec 31, 2022filed Feb 16, 2023 | FY2021ended Dec 31, 2021filed Feb 24, 2022 | FY2020ended Dec 31, 2020filed Feb 19, 2021 | FY2019ended Dec 31, 2019filed Feb 21, 2020 | FY2018ended Dec 31, 2018filed Oct 24, 2019 | FY2017ended Dec 31, 2017filed Feb 21, 2020 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,720 | 2,511 | 2,567 | 2,569 | 2,509 | 1,929 | 2,285 | 2,845 | 2,811 |
| Cost of revenue | 1,233 | 1,138 | 1,126 | 1,094 | 1,082 | 874 | 936 | 1,243 | 1,190 |
| Gross profit | 1,487 | 1,373 | 1,441 | 1,475 | 1,427 | 1,055 | 1,349 | 1,602 | 1,621 |
| Research and development | 114 | 99 | 94 | 100 | 101 | 87 | 133 | 172 | 172 |
| Selling, general and administrative | 1,157 | 1,158 | 1,057 | 1,056 | 1,020 | 925 | 980 | 1,131 | 1,062 |
| Operating income | 216 | (1,038) | 32 | 319 | 306 | 44 | 236 | 298 | 387 |
| Other income (expense) | (2) | 0 | (23) | 3 | 2 | (1) | 2 | 3 | — |
| Pretax income | 177 | (1,085) | (55) | 284 | 255 | (20) | 234 | 301 | 387 |
| Income tax | 130 | 34 | 45 | 46 | (9) | (62) | 50 | 70 | 86 |
| Net income | 47 | (1,119) | (100) | 243 | 341 | 33 | 218 | 231 | 301 |
| Diluted EPS ($) | 0.28 | (6.50) | (0.60) | 1.37 | 1.92 | 0.20 | 1.60 | 1.80 | 2.35 |
| Diluted shares (millions) | 169 | 172 | 167 | 178 | 178 | 164 | 136 | 128 | 128 |
Balance sheet
| Millions of dollars | FY2025ended Dec 31, 2025filed Feb 12, 2026 | FY2024ended Dec 31, 2024filed Feb 13, 2025 | FY2023ended Dec 31, 2023filed Feb 15, 2024 | FY2022ended Dec 31, 2022filed Feb 16, 2023 | FY2021ended Dec 31, 2021filed Feb 24, 2022 | FY2020ended Dec 31, 2020filed Feb 19, 2021 | FY2019ended Dec 31, 2019filed Feb 21, 2020 | FY2018ended Dec 31, 2018filed Oct 24, 2019 | FY2017ended Dec 31, 2017filed Feb 21, 2020 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1,212 | 1,069 | 940 | 607 | 1,074 | 889 | 211 | 0 | — |
| Short-term investments | — | — | — | — | — | — | — | — | — |
| Total current assets | 2,027 | 1,788 | 1,744 | 1,425 | 1,836 | 1,591 | 1,002 | 787 | — |
| Total assets | 5,679 | 5,351 | 6,605 | 6,587 | 6,574 | 6,876 | 6,158 | 5,842 | 5,993 |
| Total current liabilities | 853 | 879 | 781 | 1,237 | 1,208 | 1,685 | 709 | 641 | — |
| Long-term debt | 1,448 | 1,278 | 1,398 | 871 | 883 | 908 | 1,321 | 0 | — |
| Total debt | 1,448 | 1,510 | 1,629 | 1,891 | 1,748 | 2,681 | 1,329 | 0 | — |
| Total liabilities | — | — | — | — | — | — | — | — | — |
| Stockholders’ equity | 3,106 | 2,935 | 4,174 | 4,207 | 4,058 | 3,721 | 3,540 | 4,823 | — |
| Shares outstanding (millions) | 164 | 172 | 172 | 163 | 162 | 160 | 159 | — | — |
Cash flow statement
| Millions of dollars | FY2025ended Dec 31, 2025filed Feb 12, 2026 | FY2024ended Dec 31, 2024filed Feb 13, 2025 | FY2023ended Dec 31, 2023filed Feb 15, 2024 | FY2022ended Dec 31, 2022filed Feb 16, 2023 | FY2021ended Dec 31, 2021filed Feb 24, 2022 | FY2020ended Dec 31, 2020filed Feb 19, 2021 | FY2019ended Dec 31, 2019filed Feb 21, 2020 | FY2018ended Dec 31, 2018filed Oct 24, 2019 | FY2017ended Dec 31, 2017filed Feb 21, 2020 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 276 | 337 | 276 | 183 | 362 | 284 | 398 | 400 | 359 |
| Capital expenditures | 45 | 34 | 58 | 76 | 55 | 48 | 78 | 72 | 49 |
| Free cash flow (CFO − capex) | 230 | 303 | 218 | 107 | 307 | 236 | 320 | 328 | 310 |
| Depreciation and amortization | 116 | 123 | 136 | 138 | 118 | 122 | 120 | 130 | 121 |
| Share repurchases | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — |
Insider activity
Form 4 filings by officers, directors and 10% owners, November 16, 2024 to November 16, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.
The last 25 transactions
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Nov 1, 2026 | Keel Paul A | Chairman and CEO, Director | tax withholding | 54,197 | $23.51 | $1M | 497,107 | Nov 2, 2026 |
| Aug 25, 2026 | Acurio Veronica | President, Orthodontics | tax withholding | 7,710 | $27.47 | $212K | 48,806 | Aug 27, 2026 |
| Aug 25, 2026 | Befidi Robert | President, Diagnostics | tax withholding | 5,147 | $27.47 | $141K | 45,785 | Aug 27, 2026 |
| Aug 25, 2026 | Hammes Eric D. | Chief Financial Officer | tax withholding | 10,885 | $27.47 | $299K | 99,913 | Aug 27, 2026 |
| Aug 25, 2026 | Nilsson Stefan | President, Nobel Biocare | tax withholding | 804 | $27.47 | $22K | 61,560 | Aug 27, 2026 |
| Aug 20, 2026 | Reis Mischa | SVP, Strategy & Bus. Dev. | open-market sale10b5-1 | 8,000 | $27.50 | $220K | 27,321 | Aug 24, 2026 |
| Aug 18, 2026 | Keel Paul A | Chief Executive Officer, Director | award | 179,730 | $0.00 | — | 551,304 | Aug 20, 2026 |
| May 25, 2026 | Keel Paul A | Chief Executive Officer, Director | tax withholding | 12,811 | $23.43 | $300K | 371,574 | May 27, 2026 |
| May 19, 2026 | Carruthers Wendy | Director | award | 9,330 | $0.00 | — | 59,940 | May 21, 2026 |
| May 19, 2026 | Tsingos Christine A | Director | award | 9,330 | $0.00 | — | 59,930 | May 21, 2026 |
| May 19, 2026 | Jain Vivek | Director | award | 9,330 | $0.00 | — | 52,945 | May 21, 2026 |
| May 19, 2026 | Gallahue Kieran | Director | award | 9,330 | $0.00 | — | 54,010 | May 21, 2026 |
| May 19, 2026 | Pierce James Andrew | Director | award | 9,330 | $0.00 | — | 18,485 | May 21, 2026 |
| May 19, 2026 | Raskas Daniel | Director | award | 9,330 | $0.00 | — | 54,010 | May 21, 2026 |
| May 19, 2026 | Huennekens R Scott | Director | award | 12,585 | $0.00 | — | 82,105 | May 21, 2026 |
| Feb 25, 2026 | Hammes Eric D. | Chief Financial Officer | tax withholding | 2,045 | $29.59 | $61K | 94,743 | Feb 27, 2026 |
| Feb 25, 2026 | Hammes Eric D. | Chief Financial Officer | award | 16,055 | $0.00 | — | 110,798 | Feb 27, 2026 |
| Feb 25, 2026 | Acurio Veronica | President, Orthodontics | tax withholding | 1,412 | $29.59 | $42K | 48,911 | Feb 27, 2026 |
| Feb 25, 2026 | Acurio Veronica | President, Orthodontics | award | 7,605 | $0.00 | — | 56,516 | Feb 27, 2026 |
| Feb 25, 2026 | Nilsson Stefan | President, Nobel Biocare | tax withholding | 182 | $29.59 | $5K | 54,759 | Feb 27, 2026 |
| Feb 25, 2026 | Nilsson Stefan | President, Nobel Biocare | award | 7,605 | $0.00 | — | 62,364 | Feb 27, 2026 |
| Feb 25, 2026 | Reis Mischa | SVP, Strategy & Bus. Dev. | tax withholding | 2,976 | $29.59 | $88K | 29,406 | Feb 27, 2026 |
| Feb 25, 2026 | Reis Mischa | SVP, Strategy & Bus. Dev. | award | 5,915 | $0.00 | — | 35,321 | Feb 27, 2026 |
| Feb 25, 2026 | Nance Mark E | General Counsel | award | 12,675 | $0.00 | — | 81,252 | Feb 27, 2026 |
| Feb 25, 2026 | Nance Mark E | General Counsel | tax withholding | 3,368 | $29.59 | $100K | 68,577 | Feb 27, 2026 |
Full insider history for Envista Holdings Corporation Common stock, $0.01 par value per share, or insider activity across all companies. A record of filings, not a recommendation.
Tracked funds holding it
1 of the tracked managers held NVST in their latest 13F filing, through November 12, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded NVST by quarter.
| Fund | Manager | Quarter | Value | Shares | Weight | Move |
|---|---|---|---|---|---|---|
| Renaissance Technologies | Peter Brown | Q3 2026 | $38M | 2M | 0.05% | added +6.5% |
Sources
Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.
- Filer
- Envista Holdings Corp, CIK 1757073 on EDGAR
- Extract generated
- November 16, 2026
- Withheld
- 6 line-years whose four quarters do not sum to the filed year: gross profit FY2019, revenue FY2019, cost of revenue FY2020, operating income FY2020, opex sga FY2020, pretax income FY2020
- Repaired
- 1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: operating income FY2023
XBRL concepts behind each line
Income statement
RevenueFromContractWithCustomerExcludingAssessedTaxCostOfGoodsAndServicesSoldGrossProfitResearchAndDevelopmentExpenseSellingGeneralAndAdministrativeExpenseOperatingIncomeLossOtherNonoperatingIncomeExpenseIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncomeTaxExpenseBenefitNetIncomeLossEarningsPerShareDilutedWeightedAverageNumberOfDilutedSharesOutstandingBalance sheet
CashAndCashEquivalentsAtCarryingValueAssetsCurrentAssetsLiabilitiesCurrentLongTermDebtNoncurrentLongTermDebt, LongTermDebt+short-term, noncurrent, noncurrent+DebtCurrentStockholdersEquitydei:EntityCommonStockSharesOutstandingCash flow statement
NetCashProvidedByUsedInOperatingActivitiesPaymentsToAcquirePropertyPlantAndEquipmentDepreciationDepletionAndAmortizationThe data
The statements on this page as files, generated November 16, 2026.
- JSON file
/data/financials/NVST.json